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Huntington’s disease: of mice and men
Emma Yhnell
The genetic cause of Huntington’s disease (HD) 
was identified as a trinucleotide expansion within the first 
exon of the huntingtin gene in 1993 [1]. As a result of this, 
numerous genetically modified animals have been created 
in an attempt to replicate the primary genetic cause of the 
human condition.
A large number of genetically modified animal 
models of HD are now available for use in research 
including large animal models such as non-human 
primates, sheep and pigs. However, by far the most 
commonly used genetically modified animal model of 
HD is the mouse. Knock-in mouse models in particular, 
contain the huntingtin mutation in the appropriate 
proteomic and genomic context to replicate the human 
condition. Mouse models of HD offer comparative ease of 
genetic manipulation and they are relatively inexpensive 
to maintain. However, the relative life span of a mouse in 
comparison to a human and the lack of gross structural 
neuroanatomical similarities is disadvantageous in 
modelling the human condition of HD. 
A triad of motor, psychiatric and cognitive 
symptoms is described in the human condition of HD, 
with cognitive and psychiatric symptoms often occurring 
prior to the onset of motor symptoms [2]. While motor 
symptoms can be readily characterised in mouse models of 
HD utilising apparatus such as the rotarod, balance beam 
or staircase, cognitive and psychiatric symptoms are often 
more difficult to determine in mouse models of HD. 
Operant testing apparatus allows the characterisation 
of cognitive dysfunction in mouse models of HD [3]. 
Although, in these mouse models it can often be difficult to 
tease out specific cognitive deficits from motor problems 
or general measures of apathy or motivation. However, 
cognitive problems are considerably burdensome for 
people living with HD, often from very early in the disease 
progression. Therefore, in determining how accurately a 
mouse model represents the human condition of HD, it is 
important to appropriately characterise cognitive changes 
in mouse models of the disease. 
Cognitive changes are often characterised in a 
longitudinal manner, which requires repeated testing 
of animals in a battery of operant tasks [4]. Although 
different experimental designs can be used to minimise 
the practice effects of repeated cognitive testing, repeated 
cognitive testing in the same animals has been shown 
to modify HD related symptoms [5]. Furthermore, a 
cognitive training intervention utilising a five-choice serial 
reaction time task of attention, implemented early within 
the disease progression of HD, was shown to modify 
subsequent disease related behaviours in both wild type 
and HD mice [6]. Initial training, given at 4 months of age 
significantly changed subsequent behaviour 8 months later 
when the animals were tested in the same task. However, 
the possible transfer effects of such a cognitive training 
intervention into broader cognitive domains and tasks 
remain unclear. Thus, it future studies it may be necessary 
to include another task which tests similar cognitive 
functions to see if there is any generalisation to the benefits 
of the cognitive training intervention. Furthermore, 
modifications in response time were observed as a result 
of the cognitive training intervention, these are reported 
to be indicative of motor function. Therefore, it may be 
the case that cognitive training can influence the motor 
phenotype, although the possible mechanisms behind such 
an interaction remain unclear. Cognitive training studies 
in mouse models of HD have important implications for 
the longitudinal behavioural characterisation of HD mice, 
as repeatedly testing HD mice in cognitive tasks may well 
mask or modify the behavioural changes observed.
Pre-clinical studies suggest that cognitive training 
may provide some therapeutic benefit in HD. However, 
to maximise the beneficial effects of cognitive training in 
HD, it may be possible to use it in conjunction with other 
interventions in a combinatorial approach. For example, 
it could be combined with pharmacological interventions, 
transplantation therapies or non-pharmacological 
interventions such as exercise or changes to diet. 
In conclusion, genetically modified mice were 
created in an attempt to model the human condition of 
HD, but the ultimate aim of this type of research is to 
translate and progress these findings into the patient clinic. 
Therefore, the next step is to translate the pre-clinical 
findings regarding cognitive training in mouse models of 
HD into the patient clinic. The first stage is to investigate 
the feasibility of such an intervention in this specific 
patient population, before determining if there are any 
functional benefits produced as a result of the intervention.
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